S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
MarketBeat Week in Review – 5/29 - 6/2
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
MarketBeat Week in Review – 5/29 - 6/2
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
MarketBeat Week in Review – 5/29 - 6/2
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
MarketBeat Week in Review – 5/29 - 6/2
NASDAQ:CTSO

Cytosorbents (CTSO) Stock Forecast, Price & News

$3.08
+0.08 (+2.67%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.98
$3.12
50-Day Range
$2.37
$3.58
52-Week Range
$1.03
$4.59
Volume
33,176 shs
Average Volume
61,336 shs
Market Capitalization
$135.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Cytosorbents MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
78.6% Upside
$5.50 Price Target
Short Interest
Bearish
2.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$40,505 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.45) to ($0.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

822nd out of 983 stocks

Surgical & Medical Instruments Industry

80th out of 98 stocks


CTSO stock logo

About Cytosorbents (NASDAQ:CTSO) Stock

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.

Receive CTSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

CTSO Stock News Headlines

Biden's latest bailout--terrible for America?
And a consultant for the Dept. of Defense (Joel Litman) says this is all leading to an event in the next 20 months that could help some get vastly wealthier… but also make it harder than ever to hang onto any money you make.This might be the most important development affecting you and your money over the next few years—
CytoSorbents: Q1 Earnings Snapshot
Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
CytoSorbents Reports First Quarter 2023 Results
Cytosorbents (CTSO) to Release Earnings on Tuesday
Cytosorbents Co. (NASDAQ:CTSO) Short Interest Update
6CTSO : CytoSorbents Earnings Preview
See More Headlines

CTSO Price History

CTSO Company Calendar

Last Earnings
3/09/2023
Today
6/03/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTSO
Employees
221
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+78.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-32,810,000.00
Pretax Margin
-91.02%

Debt

Sales & Book Value

Annual Sales
$29.35 million
Book Value
$0.66 per share

Miscellaneous

Free Float
40,394,000
Market Cap
$135.38 million
Optionable
Optionable
Beta
0.70

Key Executives

  • Phillip P. ChanPhillip P. Chan
    Chief Executive Officer & Director
  • Vincent J. Capponi
    President & Chief Operating Officer
  • Steven Sisk
    Director-Clinical Operations
  • Efthymios N. Deliargyris
    Chief Medical Officer
  • Christopher Cramer
    Vice President-Business Development













CTSO Stock - Frequently Asked Questions

Should I buy or sell Cytosorbents stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTSO shares.
View CTSO analyst ratings
or view top-rated stocks.

What is Cytosorbents' stock price forecast for 2023?

1 brokers have issued 12-month target prices for Cytosorbents' stock. Their CTSO share price forecasts range from $5.50 to $5.50. On average, they anticipate the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 78.6% from the stock's current price.
View analysts price targets for CTSO
or view top-rated stocks among Wall Street analysts.

How have CTSO shares performed in 2023?

Cytosorbents' stock was trading at $1.55 at the beginning of 2023. Since then, CTSO stock has increased by 98.7% and is now trading at $3.08.
View the best growth stocks for 2023 here
.

Are investors shorting Cytosorbents?

Cytosorbents saw a increase in short interest in May. As of May 15th, there was short interest totaling 800,600 shares, an increase of 19.7% from the April 30th total of 669,100 shares. Based on an average daily trading volume, of 72,600 shares, the days-to-cover ratio is currently 11.0 days. Currently, 2.1% of the shares of the stock are short sold.
View Cytosorbents' Short Interest
.

When is Cytosorbents' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our CTSO earnings forecast
.

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) issued its earnings results on Thursday, March, 9th. The medical research company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.16. The medical research company earned $9.39 million during the quarter, compared to analysts' expectations of $9.40 million. Cytosorbents had a negative net margin of 87.94% and a negative trailing twelve-month return on equity of 82.56%.

What is Phillip Chan's approval rating as Cytosorbents' CEO?

11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend.

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

Who are Cytosorbents' major shareholders?

Cytosorbents' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Skylands Capital LLC (6.27%), Granahan Investment Management LLC (3.57%), Sargent Investment Group LLC (2.77%), CM Management LLC (1.02%), Jacob Asset Management of New York LLC (0.54%) and Dimensional Fund Advisors LP (0.20%). Insiders that own company stock include Al Kraus, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi.
View institutional ownership trends
.

How do I buy shares of Cytosorbents?

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $3.08.

How much money does Cytosorbents make?

Cytosorbents (NASDAQ:CTSO) has a market capitalization of $135.38 million and generates $29.35 million in revenue each year. The medical research company earns $-32,810,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

How many employees does Cytosorbents have?

The company employs 221 workers across the globe.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.cytosorbents.com. The medical research company can be reached via phone at (732) 329-8885, via email at avogel@cytosorbents.com, or via fax at 732-329-8650.

This page (NASDAQ:CTSO) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -